Also, the small‐molecule inhibitor of PICK1 FSC231 (Thorsen et al, 2010) as well as a myristoylated GluA2 inhibitory peptide (Garry et al, 2003) failed to elicit a significant effect on the PWT (Fig EV4B and C), whereas gabapentin, a first‐line treatment for neuropathic pain, reversed PWT to baseline levels of the contralateral paw and prior to nerve injury of the ipsilateral paw (Fig EV4D). This evidence concerns the gene GRIA2 and neuropathic pain.